Loading briefing details...
Loading briefing details...
News Briefs
By: Brief The Press
Category:Business,Health,Science & Environment
May 28, 2026
This innovation significantly advances drug discovery and environmental toxicology by offering a precise, non-mammalian model. It enables more accurate species-specific metabolic profiling, reduces reliance on animal testing, and provides critical insights into drug safety and aquatic ecosystem health, ultimately accelerating safer pharmaceutical development.
Creative Diagnostics, a leading supplier in biologics quality control, proudly announces the launch of its innovative SpeX™ Rainbow Trout Hepatocytes. This advanced in vitro model addresses the critical need for accurate, species-specific metabolic profiling in early drug discovery and environmental safety assessments. Understanding metabolic stability is paramount, as poor stability can lead to insufficient drug exposure, toxic metabolites, or adverse reactions, directly impacting a compound's progression.
Leveraging the complete enzyme system, including CYP450 (Phase I) and UGT (Phase II), found in rainbow trout livers, SpeX™ Hepatocytes offer unique insights. Their distinct substrate specificity and metabolic kinetics, compared to mammalian models, are invaluable for predicting species-specific metabolic variations and assessing compound clearance. This also makes them crucial for researching environmental pollutants and drug residues in aquatic systems.
By providing accurate metabolic clearance data, this model significantly accelerates drug development and enriches pharmacology and environmental toxicology studies. Creative Diagnostics' commitment to innovative research tools is evident, offering a powerful alternative to traditional mammalian models. For comprehensive information on SpeX™ Rainbow Trout Hepatocytes and related ADME products, please visit the Creative Diagnostics website.